APR 22·Stock Titan▲
BioLife’s CryoCase wins award for tackling frozen therapy bag failures
BioLife Solutions (NASDAQ: BLFS) has won the INTERPHEX 2026 Biotech Innovation Award for its CellSeal® CryoCase, a rigid cryogenic containment system designed to prevent failures common with flexible cryobags in cell and gene therapy manufacturing. Launched in 2025, CryoCase provides reinforced structural protection during freezing, liquid nitrogen storage, and distribution, addressing a significant industry need for improved containment and visual inspection of frozen biologic materials. This award validates the product's importance as CGT programs move towards commercialization and regulatory scrutiny increases.
APR 1·Stock Titan▼
BioLife Solutions (BLFS) executive sells 2,577 shares under 10b5-1 plan
Karen A. Foster, Chief Quality and Operations at BioLife Solutions (BLFS), sold 2,577 shares of common stock at a weighted average price of $19.17 per share. This transaction was conducted under a pre-arranged Rule 10b5-1(c) trading plan adopted in December 2025. Following the sale, Foster directly holds 108,758 shares of BioLife Solutions common stock.
